1
|
Allard C, Desgagné V, Patenaude J, Lacroix M, Guillemette L, Battista MC, Doyon M, Ménard J, Ardilouze JL, Perron P, Bouchard L, Hivert MF. Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns. Epigenetics 2015; 10:342-51. [PMID: 25800063 PMCID: PMC4622547 DOI: 10.1080/15592294.2015.1029700] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Revised: 02/16/2015] [Accepted: 03/10/2015] [Indexed: 10/23/2022] Open
Abstract
Leptin is an adipokine that acts in the central nervous system and regulates energy balance. Animal models and human observational studies have suggested that leptin surge in the perinatal period has a critical role in programming long-term risk of obesity. In utero exposure to maternal hyperglycemia has been associated with increased risk of obesity later in life. Epigenetic mechanisms are suspected to be involved in fetal programming of long term metabolic diseases. We investigated whether DNA methylation levels near LEP locus mediate the relation between maternal glycemia and neonatal leptin levels using the 2-step epigenetic Mendelian randomization approach. We used data and samples from up to 485 mother-child dyads from Gen3G, a large prospective population-based cohort. First, we built a genetic risk score to capture maternal glycemia based on 10 known glycemic genetic variants (GRS10) and showed it was an adequate instrumental variable (β = 0.046 mmol/L of maternal fasting glucose per additional risk allele; SE = 0.007; P = 7.8 × 10(-11); N = 467). A higher GRS10 was associated with lower methylation levels at cg12083122 located near LEP (β = -0.072 unit per additional risk allele; SE = 0.04; P = 0.05; N = 166). Direction and effect size of association between the instrumental variable GRS10 and methylation at cg12083122 were consistent with the negative association we observed using measured maternal glycemia. Lower DNA methylation levels at cg12083122 were associated with higher cord blood leptin levels (β = -0.17 log of cord blood leptin per unit; SE = 0.07; P = 0.01; N = 170). Our study supports that maternal glycemia is part of causal pathways influencing offspring leptin epigenetic regulation.
Collapse
Key Words
- BMI, Body Mass Index
- CDA, Canadian Diabetes Association
- CHUS, Centre hospitalier universitaire de Sherbrooke
- CpGs, CG dinucleotides
- DNA methylation
- DNAm, DNA methylation
- DOHaD, Developmental Origins of Health and Disease
- GCT, Glucose Challenge Test
- GDM, Gestational Diabetes Mellitus
- GRS, Genetic Risk Score
- IADPSG, International Association of the Diabetes and Pregnancy Study Groups
- IV, Instrumental Variable
- MAGIC, Meta-Analyses of Glucose and Insulin-related traits Consortium
- MDS, Multidimensional Scaling
- MR, Mendelian Randomization
- Mendelian randomization
- OGTT, Oral Glucose Tolerance Test
- SGA, Small for Gestational Age
- SNPs, Single Nucleotide Polymorphisms
- TSLS, Two-Stage Least Square
- fetal programming
- gestational diabetes
- glycemia
- leptin
- mQTL, methylation Quantitative Trait Locus
- obesity
- pregnancy
Collapse
Affiliation(s)
- C Allard
- Department of Mathematics; Faculty of Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
| | - V Desgagné
- Department of Biochemistry; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de Recherche Clinique ECOGENE-21; CSSS de Chicoutimi; Chicoutimi, QC Canada
| | - J Patenaude
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
| | - M Lacroix
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
| | - L Guillemette
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
| | - MC Battista
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
| | - M Doyon
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
| | - J Ménard
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
| | - JL Ardilouze
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
| | - P Perron
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
| | - L Bouchard
- Department of Biochemistry; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
- Centre de Recherche Clinique ECOGENE-21; CSSS de Chicoutimi; Chicoutimi, QC Canada
| | - MF Hivert
- Department of Medicine; Faculty of Medicine and Health Sciences; Université de Sherbrooke; Sherbrooke, QC Canada
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC Canada
- Department of Population Medicine; Harvard Pilgrim Health Care Institute; Harvard Medical School; Boston, MA USA
- Diabetes Unit; Massachusetts General Hospital; Boston, MA USA
| |
Collapse
|